Planned Mode of Delivery After Caesarean: a Comparative Prospective National Population-based Cohort Study
Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · Jun 28, 2022
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best way for women who have had one previous caesarean delivery to give birth again. Women in this situation usually have two choices: they can try for a vaginal delivery after caesarean (called TOLAC) or opt for another caesarean delivery (called ERCD). The researchers want to find out if TOLAC is just as safe as ERCD, particularly in terms of health outcomes for the baby and the mother. This is important because many studies have suggested that TOLAC might carry some risks, but these studies often included women with more complicated medical histories.
To participate in this study, women need to be 18 years or older, pregnant with a single baby, and at least 34 weeks along in their pregnancy. They should also be comfortable using computers. Women who do not wish to join the study or have had multiple previous caesareans are not eligible. If they choose to participate, they can expect to be involved in discussions with their doctors to help make the best decision for their delivery. This trial is currently recruiting participants, and it aims to provide clearer information to help women make informed choices about their delivery options.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant women age of 18 years or older
- • Women admitted to the labour ward at gestational age ≥ 34 weeks
- • Women with a singleton pregnancy
- • Women with one previous caesarean delivery
- * Computer savvy-women Exclusion Criteria:
- Exclusion criteria :
- • Women who oppose to participation in the study
- • Age \< 18 years
- • Women admitted to the labour ward at gestational age \< 34 weeks
- • Women with multiple pregnancy
- • Women with more than one previous caesarean or more than one uterine scar
- • Women who do not understand the French language
- • Women under judicial protection
About Assistance Publique Hopitaux De Marseille
Assistance Publique - Hôpitaux de Marseille (AP-HM) is a leading public healthcare institution in France, dedicated to providing high-quality medical care and advancing research in various clinical fields. As a prominent sponsor of clinical trials, AP-HM is committed to fostering innovation and improving patient outcomes through rigorous scientific investigation. With a multidisciplinary approach, the institution collaborates with a network of healthcare professionals, researchers, and academic partners to facilitate cutting-edge studies that address critical health challenges. AP-HM's dedication to ethical standards and patient safety underscores its role as a trusted leader in clinical research and healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Marseille, , France
Marseille, Bouches Du Rhône, France
Patients applied
Trial Officials
François CREMIEUX
Study Director
ASSITANCE PUBLIQUE HOPITAUX MARSEILLE
Julie BLANC
Principal Investigator
ASSITANCE PUBLIQUE HOPITAUX MARSEILLE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials